• The Future of Drug Development: AI, RWD, and Regulatory Insights feat. Evidera's Ariel Berger

  • Mar 31 2025
  • Length: 42 mins
  • Podcast

The Future of Drug Development: AI, RWD, and Regulatory Insights feat. Evidera's Ariel Berger

Listen for free

View show details

  • Summary

  • In this episode of The ConcertAI Podcast, Jeff Elton, CEO of ConcertAI, engages with Ariel Berger, Executive Director of Integrated Solutions of Evidera, part of the PPD™ clinical research business of Thermo Fisher Scientific, to explore the innovative uses of real-world data (RWD) in regulatory settings, particularly in oncology. They discuss the critical role of RWD in shaping clinical trials and supporting regulatory decisions, emphasizing its growing importance in the regulatory approval process. The conversation also delves into the complexities of integrating AI and advanced data technologies to enhance trial designs and outcomes, highlighting how these tools are revolutionizing drug development efficiency and precision in patient care. Through insightful dialogue, the episode illuminates the transformative impact of these technologies on the future of healthcare and precision medicine.


    Website
    www.ConcertAI.com

    LinkedIn
    www.linkedin.com/company/concertai/

    Twitter
    www.twitter.com/concertai
    Show more Show less
Show more Show less
adbl_web_global_use_to_activate_webcro768_stickypopup

What listeners say about The Future of Drug Development: AI, RWD, and Regulatory Insights feat. Evidera's Ariel Berger

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available